Ready to engage your care community in research?
We’re currently supporting recruitment for a Phase 3 study of a new treatment for agitation in persons with Alzheimer’s disease. We’re seeking care community partners willing to engage in educational events — and to connect eligible residents to participate in the study at clinical trial sites — in the following cities:
- Rogers, Arkansas
- Oklahoma City, Oklahoma
- Tom’s River, New Jersey
- New Hyde Park, New York
- Suwanee, Georgia
- San Diego, California
- Glendale, California
Located in these areas or know of communities that are? Contact us today to learn more.
Telehealth Caregiver Support Study: Recruitment Success!
Connecting Elephants and Alzheimer’s
Giving new meaning to the phrase: “memory like an elephant,” check out what we can learn from elephants about Alzheimer’s in this fascinating read from Fortune, which also delves into the tau vs. beta amyloid debate and more. Per the piece, “…there seems to be little evidence that older elephants suffer from mental decline. So far, in the handful of brains of older elephants that have been examined post-mortem, there’s also no evidence of a buildup of amyloid plaques.” What current research studies do you find most intriguing? Send us an email and tell us about it, and we’ll share it in our next newsletter.
This Alzheimer’s News Today article announces the introduction of the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS), the largest genetic database on Alzheimer’s disease. This database will soon make large sets of DNA sequences available to researchers. What do you think of this upcoming resource? Tell us on our LinkedIn page.
Surprising Results In PET Tracer Study
Another important, yet surprising, finding was announced at AAIC18. According to the piece from Alzforum about it, “several research groups are exploring the potential of HDAC inhibitors as AD therapeutics, with at least two trials currently enrolling. The recent development of a PET tracer that recognizes class I HDACs in the brains of living people provides a valuable tool for such trials. Now, however, the first HDAC PET data from people with AD upends previous findings.” Stay tuned to our LinkedIn page for more updates like this one.